ClinicalTrials.gg
CompletedNCT07002060Updated Feb 2, 2026

Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

A Phase 3 interventional study of Yellow fever vaccine (live) and YF vaccine (live) in Yellow Fever Immunization, sponsored by Sanofi. Completed at 7 sites in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Yellow Fever Vaccine in Yellow Fever — 3 open to participants now, 7 under way, 1 of them phase 3. Yellow Fever Vaccine · Yellow Fever.

Enrollment
5th of 18
640 · median 181
Started
2025
with 2 others
Phase 3
6 of 18
1 open now
Registered
17th of 18
by date
Lead sponsor
2 of 18
Sanofi

Among the 18 studies testing Yellow Fever Vaccine in Yellow Fever, this one is the 5th largest by enrollment, is one of 3 that started in 2025, is one of 6 in phase 3, and was the 17th registered.

Yellow Fever

52 studies on the registry are indexed under Yellow Fever; 10 are open to participants now.

Browse Yellow Fever studies →

Open to participants now

3 of the 18 studies testing Yellow Fever Vaccine in Yellow Fever are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Yellow Fever Vaccine

Yellow Fever Vaccine: first FDA approval 1999 (Yf-Vax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Yellow Fever studies recruiting now, 1 sets no upper age limit and 6 stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Yellow Fever Vaccine in Yellow Fever, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety of vYF (investigational vaccine) compared to the safety of YF-VAX (YF licensed vaccine) in adults aged 18 years up to 60 years.

Study details include:

  • The study duration will be up to approximately 6 months.
  • One single dose of the study intervention (vYF or YF-VAX) will be administered subcutaneously at the 1st visit.
  • The visit(V) frequency will be Day(D) 01 (V01) and D29 (V02). Two telephone calls will be planned at D15 and Month(M)6.

Number of Participants:

A total of 640 participants are expected to be included in the study in a 3:1 ratio (vYF: YF-VAX):

Group 1: vYF; N=480 Group 2: YF-VAX; N=160

Study Arms and Duration:

Randomized, active control (YF-VAX). 6 months duration per participants. Eligible participants will be randomized in a 3:1 ratio to receive, subcutaneously, a single dose of vYF or YF-VAX vaccines on D01.

03

Conditions studied

  • Yellow Fever Immunization

Browse trials for

Keywords

  • Yellow fever
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged from 18 years to 60 years on the day of inclusion
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

    • Is of non-. To be considered of non-childbearing potential, a female must be for at least 1 year, or surgically sterile.

OR

-Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.

  • A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) before any dose of study intervention on D01 and will be repeated on D29 to confirm the participant is still not pregnant within the 28 days of vaccine administration
  • Able to attend all scheduled visits and to comply with all study procedures
  • Informed consent form has been signed and dated

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known history of laboratory evidence of infection
  • Known history of or seropositivity
  • Known history of flavivirus (FV) infection
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the vaccine used in the study or to a vaccine containing any of the same substances
  • Personal or family history of thymic pathology (thymoma, thymectomy, or myasthenia)
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion , including , such as leukemia or lymphoma
  • Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38°C [or ≥ 100.4°F]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
  • Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination (prior to Visit 2 on D29), except for influenza vaccination, which may be received at least 2 weeks before study vaccine. This exception includes pandemic influenza vaccines including monovalent pandemic influenza vaccines.
  • Previous vaccination against a FV disease at any time including yellow fever (YF) with an or marketed vaccine
  • Receipt of immune globulins, blood or blood-derived products in the past 6 months
  • Administration of any anti-viral within 2 months preceding the vaccination and up to the 6 weeks following the vaccination
  • Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the course of the study in another clinical study investigating a vaccine, drug, medical device, or medical procedure
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study
  • Planned travel in a YF endemic country within 6 months of investigational vaccine administration
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
640 participants (actual)

Study arms

  • Experimental
    vYF vaccine

    A single dose on Day 01

    Biological: Yellow fever vaccine (live)

  • Active comparator
    YF-VAX vaccine

    A single dose on Day 01

    Biological: YF vaccine (live)

Interventions

  • Powder and solvent for solution for injection Subcutaneous

    Also known as: vYF vaccine

  • Powder and diluent for suspension for injection Subcutaneous

    Also known as: YF-VAX vaccine, YF-VAX

06

What researchers measure

Primary outcomes

  1. Number of participants with immediate adverse events

    Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination

    Time frame: Within 30 minutes after vaccination

  2. Number of participants with solicited injection site reactions

    Solicited injection site reactions include injection site pain, erythema and swelling

    Time frame: Up to 7 days after vaccination

  3. Number of participants with solicited systemic reactions

    Solicited systemic reactions include fever, headache, malaise and myalgia

    Time frame: Up to 14 days after vaccination

  4. Number of participants with unsolicited adverse events (AEs)

    Unsolicited (spontaneously reported) AEs, not fulfilling criteria for solicited adverse reactions

    Time frame: Up to 28 days after vaccination

  5. Number of participants with medical attended adverse events (MAAEs)

    MAAEs

    Time frame: Up to 28 days after vaccination

  6. Number of participants with adverse events of special interest (AESIs)

    AESIs

    Time frame: Up to 6 months after vaccination

  7. Number of participants with serious adverse events (SAEs)

    SAEs

    Time frame: Up to 6 months after vaccination

07

Study locations

7 sites
  • The Hope Clinic of Emory University- Site Number : 8400006
    Decatur, Georgia 30030, United States
  • Velocity Clinical Research-New Orleans- Site Number : 8400004
    New Orleans, Louisiana 70119, United States
  • Johns Hopkins Bloomberg School of Public Health- Site Number : 8400009
    Baltimore, Maryland 21205, United States
  • Saint Louis University Center for Vaccine Development- Site Number : 8400001
    St Louis, Missouri 63104, United States
  • Rochester Clinical Research- Site Number : 8400005
    Rochester, New York 14610, United States
  • Velocity Clinical Research - Providence- Site Number : 8400003
    East Greenwich, Rhode Island 02818, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jan 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 3, 2025
StartActual
May 22, 2025
Primary completionActual
Jan 20, 2026
CompletionActual
Jan 20, 2026
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07002060
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
May 22, 2025
Primary completion
Jan 20, 2026
Completion
Jan 20, 2026
Last update
Feb 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yellow Fever Vaccine

Start the discussion